Daily Derm Times: May 14, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Journal Digest: May 14

This review of the latest dermatologic studies includes insights into switching PD-1 to BRAF + MEK inhibition, clinical outcomes and prognosis in atypical fibroxanthoma, and more.

Toughness Is More Than Skin-Deep: Who Cries and Who Doesn’t in a Dermatology Clinic

Hershel Dobkin, MD, FAAD, discusses the surprising truth about toughness in dermatology, unexpected patient reactions, and the emotional depth behind appearances.

Prolonged Use of Oral Corticosteroids in Atopic Dermatitis Linked to Increased Cardiovascular Risks

Extended oral corticosteroid therapy in patients with atopic dermatitis significantly increases cardiovascular and thrombotic risks, urging careful treatment evaluations.

Clinuvel Completes Enrollment in Phase III Afamelanotide Vitiligo Trial

Clinuvel's phase III trial CUV105 enrolls 200 patients, exploring afamelanotide as a promising systemic treatment for vitiligo.

UVB Phototherapy and Tofacitinib Are Effective for Combined Vitiligo Treatment

Combining tofacitinib with UVB therapy significantly enhances vitiligo treatment outcomes, improving recovery rates and quality of life for patients.

Quoin Announces Positive QRX003 Data for Pediatric Peeling Skin Syndrome

A pediatric patient with Peeling Skin Syndrome observed overall skin healing with no adverse events after 12 weeks of treatment.

AbbVie and ADARx Join Forces to Advance Next-Generation siRNA Therapies

The new partnership brings RNA-targeted innovation to dermatology-relevant disease areas like autoimmunity and cancer.

Recludix Unveils First BTK SH2 Domain Inhibitor

Recludix Pharma unveils a groundbreaking BTK SH2 inhibitor, showcasing superior selectivity and efficacy for chronic spontaneous urticaria treatment at SID 2025.